Welcome to Peplife’s research and news hub. Here you’ll find accessibly written, source-backed explanations of what science is investigating about peptides — by theme, with the necessary nuance. We discuss research; this is not usage or health advice. Everything Peplife supplies is Research Use Only (RUO).
New — monthly
Peptide Research Bulletin — August 2026
The key peptide studies and regulator decisions of 2025–2026, explained accessibly and with sources.
Molecular weight, plasma half-life, substance class and research status of 57 peptides — bundled in one clear table.
Open the peptide database →Research pillars
Metabolism
GLP-1 and the next generation
From mono- to triple-agonists and the first oral pill — how the newest metabolic peptides work.
Heart
Peptides and heart repair
Thymosin β4, elamipretide, apelin and humanin — how heart-repair research works and what isn’t proven yet.
Regulatory
FDA and peptides: what is really happening
Compounding (503A) is not approval: what the 2026 PCAC review does and doesn’t mean.
Brain
Peptides and recovery after brain injury and stroke
Excitotoxicity, inflammation and peptides like CAQK and nerinetide — successes and failed trials.
Cancer
peptides in cancer research
Peptides as address labels: targeted delivery, radioligands and the nuance of early research.
AI
AI and the future of peptide design
From searching libraries to AI design: how RFpeptides and others create new molecules.
Liver
Peptides and fatty liver (MASH)
From fatty liver (MASLD) to inflammation and fibrosis (MASH) — where peptides act.
Skin & tissue
Peptides and wound healing
GHK-Cu, KPV, LL-37 and TB-500 — how peptides may steer the phases of wound healing.
EU regulation
The EMA guideline for synthetic peptides
What the EMA guideline for synthetic peptides means for quality, impurities and documentation in the EU.
Amylin
Eloralintide and the amylin agonists
Eloralintide, cagrilintide, petrelintide and amycretin: a second pathway alongside GLP-1, and what the phase 2 data show.
Every pillar: accessible explanation, mechanism, overview table, nuance & limitations, sources with evidence level and an honest disclaimer. RUO.